DUBLIN, April 28, 2021 /PRNewswire/ -- Cosmo
Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites
investors, financial analysts as well as business and trade media
to a conference call Q&A session on the 4th of
May 2021 to discuss GI
Genius™, the first device approved by the US Food and
Drug Administration[1] (FDA) that uses artificial
intelligence to help detect potential signs of colon cancer. GI
Genius™ is also approved in Europe, Australia, Israel and the United Arab Emirates and is available under an
exclusive worldwide distribution agreement with Medtronic.
The following representatives from Cosmo will be available to
explain how GI Genius™ helps to address the
challenges of preventing colorectal cancer and empowers physicians
to detect colorectal polyps (please note that financial details
will be discussed at a later date):
Mauro Ajani, Chairman
Alessandro Della Chà, CEO
Andrea Cherubini, Head of
Artificial Intelligence
Nhan Ngo Dinh, Head of Research and
Development, AI and Biomedical IT
Niall Donnelly, CFO &
Head of Investor Relations
Date: Tuesday, May 4,
2021
Time: 04:00 pm CET
Dial-in numbers:
Switzerland / Europe, +41 (0) 58 310 50 00
United Kingdom, +44 (0) 207 107 0613
United States, +1 (1) 631 570
5613
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on
developing and commercialising products to treat selected
gastrointestinal disorders and improve endoscopy quality measures
through aiding the detection of colonic lesions. Cosmo has also
developed medical devices for endoscopy and has a partnership with
Medtronic for the global distribution of GI Genius™ its artificial
intelligence device that uses artificial intelligence to help
detect potential signs of colon cancer. Cosmo has licensed
Aemcolo® to Red Hill Biopharma Ltd. for the US and
has licensed Relafalk® to Dr. Falk Gmbh for the EU
and other countries. For additional information on Cosmo and its
products please visit the Company's website:
www.cosmopharma.com
Calendar
Annual General Meeting, Amsterdam, May 28,
2021
Half-Year 2021 Report, July 30,
2021
Contact
Niall Donnelly, CFO & Head of
Investor Relations
Cosmo Pharmaceuticals
N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com
Logo-
https://mma.prnewswire.com/media/1459450/Cosmo_Pharmaceuticals_Logo.jpg
[1] GI GeniusTM was approved by the FDA
on the 9th of April 2021:
https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-device-uses-artificial-intelligence-help-detect-potential-signs-colon
